Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate, a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma.
Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate, a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma.